Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Quoin Pharmaceuticals ( (QNRX) ) has provided an update.
On October 21, 2025, Quoin Pharmaceuticals announced that the U.S. FDA granted Orphan Drug Designation to its lead product candidate, QRX003, for treating Netherton Syndrome. This designation, which follows a similar recognition by the European Medicines Agency in May 2025, provides benefits like tax credits and market exclusivity. QRX003 is being evaluated in late-stage clinical trials, with enrollment expected to complete in early 2026, and a new drug application submission planned for later that year. The designation could facilitate QRX003’s approval pathway in the U.S., potentially making it the first approved treatment for Netherton Syndrome.
The most recent analyst rating on (QNRX) stock is a Buy with a $70.00 price target. To see the full list of analyst forecasts on Quoin Pharmaceuticals stock, see the QNRX Stock Forecast page.
Spark’s Take on QNRX Stock
According to Spark, TipRanks’ AI Analyst, QNRX is a Underperform.
Quoin Pharmaceuticals is in a challenging financial position with no revenue generation and high reliance on external financing. The technical analysis indicates a bearish trend, though some technical indicators suggest the stock may be oversold. Valuation metrics reflect the company’s lack of profitability. The combination of these factors results in a low stock score, highlighting significant risks to investors.
To see Spark’s full report on QNRX stock, click here.
More about Quoin Pharmaceuticals
Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products for rare and orphan diseases. The company’s pipeline includes products targeting conditions such as Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, and others.
Average Trading Volume: 303,374
Technical Sentiment Signal: Sell
Current Market Cap: $9.62M
For detailed information about QNRX stock, go to TipRanks’ Stock Analysis page.